| Budget Amount *help |
¥107,770,000 (Direct Cost: ¥82,900,000、Indirect Cost: ¥24,870,000)
Fiscal Year 2021: ¥19,500,000 (Direct Cost: ¥15,000,000、Indirect Cost: ¥4,500,000)
Fiscal Year 2020: ¥19,500,000 (Direct Cost: ¥15,000,000、Indirect Cost: ¥4,500,000)
Fiscal Year 2019: ¥19,500,000 (Direct Cost: ¥15,000,000、Indirect Cost: ¥4,500,000)
Fiscal Year 2018: ¥19,500,000 (Direct Cost: ¥15,000,000、Indirect Cost: ¥4,500,000)
Fiscal Year 2017: ¥29,770,000 (Direct Cost: ¥22,900,000、Indirect Cost: ¥6,870,000)
|
|---|
| Outline of Final Research Achievements |
In this research, we have developed medicinal-organic chemistry that aimed to develop new covalent drugs , which can specifically react with a target protein and inhibit its biological function under the miscellaneous biological conditions. we have focused on (1) development of covalent drugs with a CFA group targeting cancer and infectious diseases (2) finding new reactive groups suitable for selective covalent inhibition of proteins.
|
